Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
bird flu
Biotech
Arcturus doubles down on mRNA, axes several early-stage assets
Analysts said the discontinued programs—mRNA vaccines for chlamydia, gonorrhea and Lyme disease—had “low [return on investment] visibility.”
Ben Adams
,
Gabrielle Masson
May 13, 2025 1:32pm
CDC data on influenza, bird flu go missing as outbreaks escalate
Feb 19, 2025 9:45am
Labcorp launches bird flu test amid first severe case in the US
Dec 18, 2024 3:00pm
Tiba wins BARDA contract to develop RNAi flu therapeutics
Jul 11, 2024 3:35pm
CDC has 1M bird flu tests, but experts see COVID misstep repeats
Jun 20, 2024 1:34pm
Novacyt develops new tests for COVID-19, bird flu
Dec 14, 2020 8:15am
